The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients

Recent findings suggest that a fraction of EGFR-mutant non-small-cell lung cancers (NSCLC) carry additional driver mutations that could potentially affect the activity of EGFR tyrosine kinase inhibitors (TKIs). We investigated the role of concomitant KRAS, NRAS, BRAF, PIK3CA, MET and ERBB2 mutations...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancers (Basel)
Egile Nagusiak: Rachiglio, Anna Maria, Fenizia, Francesca, Piccirillo, Maria Carmela, Galetta, Domenico, Crinò, Lucio, Vincenzi, Bruno, Barletta, Emiddio, Pinto, Carmine, Ferraù, Francesco, Lambiase, Matilde, Montanino, Agnese, Roma, Cristin, Ludovini, Vienna, Montagna, Elisabetta Sara, De Luca, Antonella, Rocco, Gaetano, Botti, Gerardo, Perrone, Francesco, Morabito, Alessandro, Normanno, Nicola
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: MDPI 2019
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6468673/
https://ncbi.nlm.nih.gov/pubmed/30857358
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers11030341
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak